NEW YORK, Nov. 26 - Rosetta Biosoftware announced on Monday that it has licensed its Resolver gene-expression data-analysis system to COR Therapeutics.
Rosetta's technology will "help us lay the groundwork for the development of novel pharmaceutical products to treat cardiovascular diseases," said James N. Topper, vice president for biology at South San Francisco, Calif.-based COR Therapeutics.
Financial terms of the agreement were not disclosed.
The Resolver bioinformatics system is distributed by Rosetta, the Kirkland, Wash.-based Merck business, and Palo Alto, Calif.-based Agilent Technologies.